MedTrace Logo

Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC

NCT05421013 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-03-18

No results posted yet for this study

Summary

Open label, dose escalation to evaluate safety.

Conditions

  • Facial isSCC

Interventions

DRUG

STP705

STP705 targets TGFB-1 and COX-2 mRNA respectively.

Sponsors & Collaborators

  • Sirnaomics

    lead INDUSTRY

Principal Investigators

  • Mark Nestor, MD · Center for Clinical and Cosmetic Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-03-29
Completion
2023-03-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05421013 on ClinicalTrials.gov